| Literature DB >> 24195965 |
Carolien A Wijsman1, Rudi Gj Westendorp, Evert Alm Verhagen, Michael Catt, P Eline Slagboom, Anton Jm de Craen, Karen Broekhuizen, Willem van Mechelen, Diana van Heemst, Frans van der Ouderaa, Simon P Mooijaart.
Abstract
BACKGROUND: Lack of physical activity leads to detrimental changes in body composition and metabolism, functional decline, and increased risk of disease in old age. The potential of Web-assisted interventions for increasing physical activity and improving metabolism in older individuals holds great promise but to our knowledge it has not been studied.Entities:
Keywords: Internet; accelerometry; aging; metabolism; physical activity; self-monitoring
Mesh:
Year: 2013 PMID: 24195965 PMCID: PMC3841355 DOI: 10.2196/jmir.2843
Source DB: PubMed Journal: J Med Internet Res ISSN: 1438-8871 Impact factor: 5.428
Figure 1Consort flowchart of participants.
Baseline characteristics of study participants (data are presented as medians with interquartile range [IQR] when skewed; alcohol use was calculated only in those who reported drinking alcohol [n=102 for intervention and n=101 for control]).
| Characteristics | Intervention (n=119) | Control (n=116) | |
|
| |||
|
| Female sex, n (%) | 47 (39.5) | 49 (42.2) |
|
| Age, yrs (mean, SD) | 64.7 (3.0) | 64.9 (2.8) |
|
| |||
|
| Moderately active | 41 (34.5) | 48 (41.4) |
|
| Moderately inactive | 36 (30.3) | 34 (29.3) |
|
| Inactive | 42 (35.3) | 34 (29.3) |
|
| |||
|
| Low | 7 (5.9) | 2 (1.7) |
|
| Intermediate | 45 (37.8) | 46 (39.7) |
|
| High | 66 (55.5) | 67 (57.8) |
|
| Current smoking | 7 (5.9) | 8 (6.9) |
|
| Alcohol use, units/wk (mean, SD) | 12.0 (8.0) | 10.2 (9.4) |
|
| |||
|
| Coronary heart diseasea | 14 (11.8) | 16 (13.8) |
|
| Arrhythmia | 10 (8.4) | 14 (12.1) |
|
| Lung emphysema | 3 (2.5) | 5 (4.3) |
|
| Stroke | 6 (5.0) | 3(2.6) |
|
| Malignancies | 17 (14.3) | 17 (14.7) |
|
| Thyroid disease | 8 (6.7) | 8 (6.9) |
|
| Antihypertensive use | 55 (46.2) | 44 (37.9) |
|
| Statin use | 31 (26.1) | 24 (20.7) |
|
| Anticoagulant use | 25 (21.0) | 20 (17.2) |
|
| Psychotropic use | 11 (9.2) | 16 (13.8) |
|
| |||
|
| Ankle monitor, counts/day (mean, SD) | 3.68×105 (1.72×105) | 3.78×105 (1.84×105) |
|
| Wrist monitor, counts/day (mean, SD) | 3.51×105 (1.10×105) | 3.39×105 (1.16×105) |
|
| MVPAb, min/day, median (IQR) | 16.8 (7.8-26.4) | 14.4 (8.2-32.0) |
|
| |||
|
| Height (cm) | 173.6 (9.9) | 172.1 (9.3) |
|
| Weight (kg) | 87.4 (15.8) | 86.3 (15.8) |
|
| BMIc (kg/m2) | 28.9 (4.7) | 29.1 (4.7) |
|
| Waist circumference (cm) | 102.3 (13.1) | 101.4 (12.3) |
|
| Hip circumference (cm) | 109.1 (9.1) | 108.7 (8.9) |
|
| Waist/hip ratio | 0.93 (0.08) | 0.93 (0.08) |
|
| Fat percentage (%) | 36.5 (7.6) | 36.4 (8.1) |
|
| Systolic blood pressure (mmHg) | 146 (18) | 145 (17) |
|
| Diastolic blood pressure (mmHg) | 86 (9) | 86 (11) |
|
| Resting heart rate (beats/min) | 72 (10) | 71 (11) |
|
| Grip strength (kg) | 37.5 (10.2) | 37.9 (10.4) |
|
| Framingham 10-year CVDd risk % | 11.9 (7.2) | 11.3 (7.5) |
|
| |||
|
| Fasting venous glucose (mmol/L) | 5.7 (0.7) | 5.7 (0.7) |
|
| Fasting insulin (mU/L) (median, IQR) | 11.5 (8.1–16.9) | 10.8 (7.0–15.8) |
|
| HbA1c (%) | 5.4 (0.3) | 5.4 (0.3) |
|
| HOMAe index (median, IQR) | 2.8 (2.0–4.4) | 2.6 (1.7–4.3) |
|
| Total cholesterol (mmol/L) | 5.7 (1.1) | 5.8 (1.0) |
|
| HDLf cholesterol (mmol/L) | 1.5 (0.5) | 1.4 (0.4) |
|
| Triglycerides (median, IQR), (mmol/L) | 1.5 (1.1–2.0) | 1.4 (1.1–2.0) |
|
| LDLg cholesterol (mmol/L) | 3.6 (1.0) | 3.6 (0.9) |
|
| Total/HDL cholesterol ratio | 4.2 (1.3) | 4.3 (1.3) |
|
| C-reactive protein (median, IQR), (mg/L) | 1.6 (0.8–3.1) | 1.4 (0.8–4.1) |
aCoronary heart disease: myocardial infarction/ angina pectoris.
bMVPA=moderate-to-vigorous physical activity.
cBMI=body mass index.
dCVD=cardiovascular disease.
eHOMA=homeostatic model assessment.
fHDL=high density lipoprotein.
gLDL=low density lipoprotein.
Figure 2Change in daily physical activity expressed as moderate-to-vigorous physical activity measured at the wrist.
Changes in parameters of metabolic health in study participants at follow-up (data represent mean differences with standard error [SE]).
|
| Intervention (n=114) | Control (n=112) |
| |||
|
| Mean difference (SE) |
| Mean difference (SE) |
|
| |
|
| ||||||
|
| Weight, kg | −1.49 (0.26) | <.001 | −0.82 (0.21) | <.001 | .046 |
|
| BMIc, kg/m2 | −0.50 (0.09) | <.001 | −0.29 (0.07) | <.001 | .068 |
|
| Waist circumference, cm | −2.33 (0.36) | <.001 | −1.29 (0.34) | <.001 | .036 |
|
| Hip circumference, cm | −1.75 (0.33) | <.001 | −1.12 (0.28) | <.001 | .14 |
|
| Waist/hip ratio | −0.008 (0.004) | .032 | −0.001 (0.003) | .81 | .16 |
|
| Fat percentage, % | −0.64 (0.23) | .003 | 0.07 (0.22) | .91 | .025 |
|
| Lean mass, kg | −0.37 ( 0.19) | .32 | −0.57 (0.20) | .033 | .46 |
|
| Systolic blood pressure (mmHg) | −2.73 (1.35) | .046 | −2.30 (1.39) | .10 | .83 |
|
| Diastolic blood pressure (mmHg) | 1.10 (0.78) | .16 | 0.10 (0.82) | .91 | .38 |
|
| Resting heart rate (beats/min) | −5.49 (0.94) | <.001 | −3.68 (0.85) | <.001 | .15 |
|
| Grip Strength (kg) | 0.31 (0.38) | .41 | 0.00 (0.34) | 1.00 | .50 |
|
| Framingham 10-year risk % | −0.54 (0.33) | .11 | −0.01 (0.31) | .98 | .24 |
|
| ||||||
|
| Fasting glucose venous (mmol/L) | −0.20 (0.05) | <.001 | −0.13 (0.04) | .001 | .31 |
|
| Ln fasting insulin (mU/L) | −0.16 (0.04) | <.001 | −0.04 (0.04) | .33 | .037 |
|
| HbA1c (%) | −0.05 (0.01) | <.001 | −0.01 (0.01) | .25 | .049 |
|
| Ln HOMAd-index | −0.20 (0.05) | <.001 | −0.06 (0.04) | .15 | .035 |
|
| Total cholesterol (mmol/L) | −0.25 (0.06) | <.001 | −0.18 (0.05) | .001 | .36 |
|
| HDLe cholesterol (mmol/L) | −0.008 ( 0.02) | .71 | −0.04 (0.02) | .033 | .27 |
|
| Ln Triglycerides (mmol/L) | −0.10 (0.03) | .003 | −0.06 (0.02) | .023 | .30 |
|
| LDLf cholesterol (mmol/L) | −0.17 (0.04) | <.001 | −0.11 (0.04) | .012 | .37 |
|
| Chol/HDL ratio | −0.20 (0.07) | .008 | −0.05 (0.05) | .32 | .10 |
|
| Ln C-reactive protein (mg/L) | −0.12 (0.08) | .11 | −0.11 (0.09) | .24 | .92 |
a P values within group.
b P value between groups.
cBMI=body mass index.
dHOMA=homeostatic model assessment.
eHDL=high-density lipoprotein.
fLDL=low-density lipoprotein (Friedewald).
Figure 3Changes in a selection of metabolic parameters.